Familial hyperchylomicronemia

Revision as of 13:48, 4 November 2016 by Vishal (talk | contribs)
Jump to navigation Jump to search

WikiDoc Resources for Familial hyperchylomicronemia

Articles

Most recent articles on Familial hyperchylomicronemia

Most cited articles on Familial hyperchylomicronemia

Review articles on Familial hyperchylomicronemia

Articles on Familial hyperchylomicronemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Familial hyperchylomicronemia

Images of Familial hyperchylomicronemia

Photos of Familial hyperchylomicronemia

Podcasts & MP3s on Familial hyperchylomicronemia

Videos on Familial hyperchylomicronemia

Evidence Based Medicine

Cochrane Collaboration on Familial hyperchylomicronemia

Bandolier on Familial hyperchylomicronemia

TRIP on Familial hyperchylomicronemia

Clinical Trials

Ongoing Trials on Familial hyperchylomicronemia at Clinical Trials.gov

Trial results on Familial hyperchylomicronemia

Clinical Trials on Familial hyperchylomicronemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Familial hyperchylomicronemia

NICE Guidance on Familial hyperchylomicronemia

NHS PRODIGY Guidance

FDA on Familial hyperchylomicronemia

CDC on Familial hyperchylomicronemia

Books

Books on Familial hyperchylomicronemia

News

Familial hyperchylomicronemia in the news

Be alerted to news on Familial hyperchylomicronemia

News trends on Familial hyperchylomicronemia

Commentary

Blogs on Familial hyperchylomicronemia

Definitions

Definitions of Familial hyperchylomicronemia

Patient Resources / Community

Patient resources on Familial hyperchylomicronemia

Discussion groups on Familial hyperchylomicronemia

Patient Handouts on Familial hyperchylomicronemia

Directions to Hospitals Treating Familial hyperchylomicronemia

Risk calculators and risk factors for Familial hyperchylomicronemia

Healthcare Provider Resources

Symptoms of Familial hyperchylomicronemia

Causes & Risk Factors for Familial hyperchylomicronemia

Diagnostic studies for Familial hyperchylomicronemia

Treatment of Familial hyperchylomicronemia

Continuing Medical Education (CME)

CME Programs on Familial hyperchylomicronemia

International

Familial hyperchylomicronemia en Espanol

Familial hyperchylomicronemia en Francais

Business

Familial hyperchylomicronemia in the Marketplace

Patents on Familial hyperchylomicronemia

Experimental / Informatics

List of terms related to Familial hyperchylomicronemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Vishal Devarkonda, M.B.B.S[2]


Synonyms and keywords: Type I hyperlipoproteinemia, Burger-Grutz syndrome, primary hyperlipoproteinemia, lipoprotein lipase deficiency, LPL deficiency, idiopathic hyperlipemia, essential hyperlipemia, familial hyperlipemia, lipase D deficiency, hyperlipoproteinemia type IA, familial chylomicronemia, familial lipoprotein lipase deficiency, and familial hyperchylomicronemia.


Overview

This very rare form is due to a deficiency of lipoprotein lipase (LPL) or altered apolipoprotein C2, resulting in elevated chylomicron which are the particles that transfer fatty acids from the digestive tract to the liver. Lipoprotein lipase is also responsible for the initial breakdown of endogenously made triacylglycerides in the form of very low density lipoprotein (VLDL). As such, one would expect a defect in LPL to also result in elevated VLDL. Its prevalence is 0.1% of the population.

Classification

Type 1A

It occurs due to deficiency of lipoprotein lipase enzyme.

Type 1B

Altered apolipoprotein C2 causes type 1B hyperlipoproteinemia

Type 1C

Presence of LPL inhibitor is the cause of type 1C hyperlipoproteinemia

Historical Perspective

Pathophysiology

  • Type I hyperlipoproteinemia is a rare autosomal recessive disorder of lipoprotein metabolism. [1][2][3]


Pathogenesis

  • Lipoprotein lipase(LPL) hydrolysis Triglyceride-rich lipoproteins (TG) such as chylomicrons and very low-density lipoproteins. It catalyzes, the removal of TG from bloodstream generating free fatty acids for tissues.
  • For full enzymatic activity, LPL requires following cofactors:-
    • Apolipoprotein C-II and apolipoprotein A-V that are LPL activators
    • Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein
    • Lipase maturation factor 1
  • Development of Type I hyperlipoproteinemia is the result of functional mutations in one of all these genes result in type I hyperlipoproteinemia.

Familial lipoprotein lipase inhibitor

    • Familial lipoprotein lipase inhibitor seems to be inherited as an autosomal dominant trait.
    • Postheparin plasma LPL activity is decreased, adipose tissue LPL activity is elevated, and plasma levels of functional apoC-I1 are normal.
  • Functionally inactive or absent lipoprotein lipase emzyme, results in massive accumulation of chylomicrons, with extremely high level of plasma triglycerides.

Causes

Differential diagnosis

Epidemiology and Demographics

Familial hyperchylomicronemia, is a rare autosomal recessive disorder of lipoprotein metabolism estimated to affect approximately one per million individuals. In some ethnic groups, the frequency of this disorder is several fold higher (i.e., French Canadians, Afrikaner).

Screening

Natural History, Complications, and Prognosis

Natural History

Complication

Prognosis

Risk Factors

Diagnosis

History/symptoms

The signs and symptoms of hyperlipoproteinemia type 1 usually begin during childhood. Approximately 25 percent of affected individuals develop symptoms before age 1. The characteristic features of hyperlipoproteinemia type 1 include: Abdominal pain (may manifest as colic in infancy) Nausea, vomiting, loss of appetite Failure to thrive in infancy Musculoskeletal pain (pain in the muscles and bones) Xanthomas (small, yellow, fat deposits in the skin) Pancreatitis Enlarged liver and spleen

Physical examination

Laboratory finding

Treatment

The main therapeutical approach of Type I hyperlipoproteinemia is based on diet treatment to reduce triglyceride (TG) levels.20 TG-lowering drugs, such as niacin and fibrates, are not effective in patients with type I hyperlipoproteinemia.21 Orlistat, a gastric lipase inhibitor that reduces fat availability, has been used successfully in the treatment of moderate and severe LPL deficiency.22 and 23 Recently, gene replacement using alipogene tiparvovec has been the very first therapy approved by European Medicines Agency for the treatment of type I hyperlipoproteinemia.24 Alipogene tiparvovec introduces a human LPL gene into the body, resulting in the production of functional LPL. 25 However, this gene therapy is indicated only in adults with genetic diagnosis of LPL deficiency who have had recurrent pancreatitis and with a residual lipoprotein mass in the circulation. 24 and 26 Thus, careful genetic screening and functional testing of LPL are required to identify patients eligible for this new therapeutic approach.

Prevention

  1. Pingitore P, Lepore SM, Pirazzi C, Mancina RM, Motta BM, Valenti L; et al. (2016). "Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia". J Clin Lipidol. 10 (4): 816–23. doi:10.1016/j.jacl.2016.02.015. PMID 27578112.
  2. Young SG, Zechner R (2013). "Biochemistry and pathophysiology of intravascular and intracellular lipolysis". Genes Dev. 27 (5): 459–84. doi:10.1101/gad.209296.112. PMC 3605461. PMID 23475957.
  3. Pasalić D, Jurcić Z, Stipancić G, Ferencak G, Leren TP, Djurovic S; et al. (2004). "Missense mutation W86R in exon 3 of the lipoprotein lipase gene in a boy with chylomicronemia". Clin Chim Acta. 343 (1–2): 179–84. doi:10.1016/j.cccn.2004.01.029. PMID 15115692.

Template:WikiDoc Sources